AppYea begins AppySleep sales but faces $3.85M convertible debt, cash crunch and control weaknesses

AppYea, Inc. (PINK: APYP)

Quick context: Financials are presented in U.S. dollars in thousands unless otherwise noted.

What's happening inside the company (straight to the point)

- Product stage: AppySleep wristband is in serial manufacturing and commercial stage; AppySleep LAB / PRO are in development aiming for FDA submissions (LAB in 2026, PRO in 2027).

- Leadership & financing moves: New CEO (Yakir Abadi) and executive chairman (Eldar Grady) appointed Aug 12, 2025; they and others invested units in July 2025 (~234,000 NIS ≈ $69.2k). Convertible note holders agreed to maturity extensions (to Feb 15, 2026) and interest freezes in exchange for repayment commitments and option issuances to consultants.

- Governance & controls: Management disclosed a material weakness in internal controls (segregation of duties) and concluded disclosure controls were not effective as of June 30, 2025.

Key financial facts & statistics (as reported)

- Shares outstanding (Aug 18, 2025): 534,758,474 shares.

- Cash and cash equivalents (June 30, 2025): 8 (i.e., $8,000).

- Total assets (June 30, 2025): 152 ($152k).

- Total current liabilities (June 30, 2025): 4,312 ($4.312M).

- Convertible loans - fair value (June 30, 2025): 3,850 ($3.85M); closing balance of convertible loans at fair value: 3,850.

- Stockholders' deficiency / accumulated deficit (June 30, 2025): total deficiency (4,160) and accumulated deficit (10,530) [$(4.160M) deficit; $(10.53M) accumulated loss].

- Revenues (six months ended June 30, 2025): 4 ($4,000). Revenues were $1 for the quarter (Q2).

- Cost of sales (six months): 8; Gross loss (six months): (4).

- Operating loss (six months): (476) [$(476k)].

- Research & development (six months): 215 [$(215k)]; Sales & marketing: 49 [$(49k)]; General & administrative: 208 [$(208k)].

- Change in fair value of convertible loans and warrant liability (six months): 314 (non‑cash gain of $314k).

- Financial expenses, net (six months): (10) [$(10k)].

- Net loss (six months): (172) [$(172k)]. (Three months ended June 30, 2025: net loss (6) vs. prior year quarter net profit 181.)

- Cash used in operating activities (six months): (213) [$(213k)].

- Options outstanding (end of period): 56,157,549; options exercisable: 53,247,551.

Positive aspects (income statement & operations)

- Revenue generation has started (AppySleep sales), even if immaterial: six‑month revenue of $4k - proof of commercialization.

- R&D remains active (capitalized R&D and continued development) - company progressing toward FDA submissions for Lab/Pro products.

- Significant non‑cash accounting benefit from convertible instrument revaluation: +314 (six months) helped reduce reported net loss.

- Management and investors injected fresh capital and negotiated debt extensions to avoid immediate conversions/defaults (short-term relief).

Negative aspects (income statement & risks)

- Revenues are negligible vs. expenses: $4k revenue vs. $472k total operating expenses (R&D + S&M + G&A ≈ $472k for six months) - unsustainable without new funding.

- Gross loss and negative gross margin: cost of sales (8) > revenue (4) → gross loss (4) for six months.

- Heavy reliance on non‑cash fair value gains from convertible instruments to offset operating losses - volatile and not sustainable as an operating benefit.

- Cash runway is extremely limited: $8k cash at June 30, 2025 and management states funds on hand likely support operations only through October 2025 without new capital.

- Large convertible liabilities (3.85M) and working capital deficit (~4.228M) create refinancing and dilution risks.

- Substantial dilution risk: numerous option grants and potential conversions (e.g., proposed conversions and very large option grants to new executives and consultants could dramatically increase share count if exercised).

- Material weakness in internal controls and ongoing legal contingency (lawsuit involving subsidiary and chairman) increase execution and compliance risk.

Immediate investor takeaways

- This is an early‑stage, low‑revenue company with product commercialization underway but with acute cash, going‑concern and dilution risks.

- Short term: watch financing progress (debt repayment/extension outcomes, private placements) and cash balance; these determine survival and near‑term development milestones.

- Medium term: key value drivers are successful market traction of AppySleep and progress toward FDA clearance for AppySleep LAB/PRO; both require capital and operating stability.

Bottom line: AppYea (PINK: APYP) has product momentum and some non‑cash accounting improvements, but negligible revenue, minimal cash on hand, large convertible liabilities, material control weaknesses and significant dilution risk. The company needs successful financing and operational execution to move from development to scalable revenue.